Estrogen Supplementation
Conditions
Brief summary
Purpose: to study the effect of estrogen replacement on muscle hypertrophy in response to 12 weeks resistance training in postmenopausal women Hypothesis: Transdermal administration of 17-β estradiol enhance the anabolic effect of resistance training on muscle mass, strength in postmenopausal women Primary outcome: Muscle hypertrophy (muscle CSA, muscle fiber type specific CSA) Secondary outcome: Messenger RiboNucleic Acid (mRNA)(real-time PCR), protein (western blotting), satellite cell proliferation and activation, Strength, functional test, muscle protein synthese. Design: Two groups of healthy postmenopausal women (½-5 years after menopause) who have not performed regular resistance exercise (\<1 times per week) the last two years. Randomized, controlled intervention study +/- transdermal administration of estrogen (17-β estradiol). Both groups perform 12 weeks of supervised progressive resistance training (3/week) aiming to induce muscle hypertrophy in the legs.
Interventions
OTHERExercise + Estrogen
12 weeks resistance training and estrogen patches
OTHERExercise + Placebo
12 weeks resistance training and placebo patches
Sponsors
University of Aarhus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Postmenopausal women, more than 6 months, but less than 5 years since last menstruation.
Exclusion criteria
* Less than 2 hours exercise with moderate to high intensity per week the last year, no regular resistance exercise the last 2 years (less than 5 exercise bouts during the last year) * No previous or present lower limb injuries which may hinder participation in strength training * No use of medicine which may influence the adaptation to strength training such as regular use of nonsteroidal anti-inflammatory drugs and use of statins, no muscle * Joint or metabolic diseases or other chronic diseases that would affect the results of the investigation, high blood pressure (\>140/90), smoking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle hypertrophy | 12 weeks | muscle cross sectional area measured by Magnetic resonance imaging (MR) -scans |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Muscle strength | 12 weeks | Maximal isometric muscle strength |
| tendon size | 12 weeks | Tendon cross sectional area measured by MR-scan |
| Muscle fiber hypertrophy | 12 weeks | Histology analysis of muscle fiber area |
| Fat mass | 12 weeks | Dual-energy X-ray absorptiometry (DXA) scan of total fat mass |
| Fat free mass | 12 weeks | Fat free mass measured by DXA scan |
| Fat cell size | 12 weeks | Analysis of fat cell size (diameter) |
Countries
Denmark
Outcome results
None listed